Drugs / MK-0482
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06413095 | Jun 2022 → Jun 2023 | head and neck squamous cell carcinoma, soft tissue sarcoma | Presage Biosciences | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT05038800 | Sep 2021 → Dec 2023 | acute myeloid leukemia, chronic myelomonocytic leukemia | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03918278 | Jun 2019 → Jun 2025 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04165070 | Dec 2019 → Feb 2032 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04165096 | Jan 2020 → Apr 2025 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT04165083 | Dec 2019 → Oct 2025 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-0482 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04165083 ↗ |
| Route | Intravenous | “IV Infusion” NCT04165070 ↗ |